Eric Baudin

Eric Baudin at Gustave Roussy leads a comprehensive adrenal malignancy program within France's premier oncology center, contributing to ENSAT collaborative trials and French national ACC management. His research has evaluated cabozantinib, lenvatinib, and immune checkpoint inhibitors in ACC, working to expand treatment options beyond mitotane-based therapy. He has been involved in molecular profiling studies identifying ACC subgroups with distinct biology and prognosis. His work integrates endocrine oncology expertise with clinical trial design for rare adrenal malignancies.